Cresilon
its biomimetic hemostatic gel, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company's Most Innovative Companies list for 2026.
- Country
- United States
Hemostatic gel
Trauma/TBI validated
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biomimetic medical adhesives | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.